DK0440146T3 - Fremstilling og anvendelse af genbanker af syntetiske humane antistoffer ("syntetiske humane antistof-biblioteker"). - Google Patents

Fremstilling og anvendelse af genbanker af syntetiske humane antistoffer ("syntetiske humane antistof-biblioteker").

Info

Publication number
DK0440146T3
DK0440146T3 DK91101094.0T DK91101094T DK0440146T3 DK 0440146 T3 DK0440146 T3 DK 0440146T3 DK 91101094 T DK91101094 T DK 91101094T DK 0440146 T3 DK0440146 T3 DK 0440146T3
Authority
DK
Denmark
Prior art keywords
synthetic human
antibody libraries
human antibody
preparation
gene banks
Prior art date
Application number
DK91101094.0T
Other languages
Danish (da)
English (en)
Inventor
Melvyn Dr Little
Frank Berthold Breitling
Thomas Dr Seehaus
Stefan Duebel
Iris Klewinghaus
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Application granted granted Critical
Publication of DK0440146T3 publication Critical patent/DK0440146T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK91101094.0T 1990-02-01 1991-01-28 Fremstilling og anvendelse af genbanker af syntetiske humane antistoffer ("syntetiske humane antistof-biblioteker"). DK0440146T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4002897A DE4002897A1 (de) 1990-02-01 1990-02-01 Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
DE4003880A DE4003880A1 (de) 1990-02-01 1990-02-09 Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")

Publications (1)

Publication Number Publication Date
DK0440146T3 true DK0440146T3 (da) 1997-03-10

Family

ID=25889601

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91101094.0T DK0440146T3 (da) 1990-02-01 1991-01-28 Fremstilling og anvendelse af genbanker af syntetiske humane antistoffer ("syntetiske humane antistof-biblioteker").

Country Status (13)

Country Link
US (1) US5840479A (fr)
EP (1) EP0440146B1 (fr)
JP (1) JPH04211395A (fr)
KR (1) KR100221897B1 (fr)
AT (1) ATE145427T1 (fr)
AU (1) AU638535B2 (fr)
CA (1) CA2035384C (fr)
DE (3) DE4002897A1 (fr)
DK (1) DK0440146T3 (fr)
ES (1) ES2097157T3 (fr)
GR (1) GR3022131T3 (fr)
IE (1) IE75220B1 (fr)
PT (1) PT96624B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6916605B1 (en) * 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
NZ243558A (en) * 1991-07-15 1994-06-27 Wellcome Found Recombinant primate antibodies and their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5316922A (en) * 1992-04-15 1994-05-31 The United States Of America As Represented By Department Of Health And Human Services Method for indentifying and expressing proteins that recognize and adhere to specific probes
WO1996038553A1 (fr) * 1995-06-02 1996-12-05 M&E Biotech A/S Procede d'identification de peptides et d'acides nucleiques biologiquement actifs
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
EP0859841B1 (fr) * 1995-08-18 2002-06-19 MorphoSys AG Banques de proteines/(poly)peptides
US6828422B1 (en) 1995-08-18 2004-12-07 Morphosys Ag Protein/(poly)peptide libraries
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
EP0877752B1 (fr) 1996-01-23 2003-05-21 The Board Of Trustees Of The Leland Stanford Junior University Procedes servant a rechercher par criblage des peptides effecteurs et des molecules d'arn transdominants
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6864235B1 (en) * 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
IL130225A0 (en) 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
ES2531551T3 (es) * 2000-04-17 2015-03-17 Dyax Corp. Métodos para construir bibliotecas de presentación de paquetes genéticos para miembros de una familia diversa de péptido
US20020110843A1 (en) * 2000-05-12 2002-08-15 Dumas David P. Compositions and methods for epitope mapping
JP4860098B2 (ja) 2000-12-18 2012-01-25 ダイアックス、コープ 遺伝的パッケージの焦点を合わせたライブラリー
WO2003040368A2 (fr) * 2001-11-09 2003-05-15 Transition Therapeutics Inc. Compositions pharmaceutiques de microciona prolifera d'eponge marine
JP2005518442A (ja) * 2001-11-20 2005-06-23 デューク・ユニバーシティー 界面バイオマテリアル
KR100528772B1 (ko) * 2002-08-02 2005-11-15 주식회사유한양행 항체 경쇄 람다 발현벡터
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
KR100604038B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 중쇄 발현벡터
WO2004013278A2 (fr) * 2002-08-02 2004-02-12 Yuhan Corporation Vecteurs d'expression
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
CN100406554C (zh) * 2003-03-28 2008-07-30 广州医学院 一种含人源导向溶栓抗体基因的大肠杆菌及其分泌产物
US7572766B2 (en) 2004-06-16 2009-08-11 Affinergy, Inc. IFBMs to promote the specific attachment of target analytes to the surface of orthopedic implants
JP5554925B2 (ja) 2006-01-20 2014-07-23 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト非小細胞肺癌における転座及び変異体rosキナーゼ
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US20070186296A1 (en) * 2006-02-02 2007-08-09 Wyeth Cloning, characterization, and application of tnfrsf19 in neurological disorders
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
US20090252745A1 (en) * 2006-09-15 2009-10-08 Duke University Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (fr) * 2007-09-14 2009-03-19 Adimab, Inc. Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3072963B1 (fr) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation et kinase ros mutante dans l'épithélioma pulmonaire humain à grandes cellules
WO2009114815A1 (fr) 2008-03-13 2009-09-17 Dyax Corp Bibliothèques de boîtiers génétiques comprenant de nouvelles conceptions de hc cdr3
PT2281078E (pt) * 2008-04-24 2015-02-05 Dyax Corp Bibliotecas de pacotes genéticos compreendendo desenhos de novas cdr1, cdr2, e cdr3 de hc e novas cdr1, cr2, e cdr3 de lc
CN101768213B (zh) 2008-12-30 2012-05-30 中国科学院遗传与发育生物学研究所 一种与植物分蘖数目相关的蛋白及其编码基因与应用
SI2881402T1 (sl) 2009-02-12 2017-12-29 Cell Signaling Technology, Inc. Ekspresija mutantnega ros pri humanem raku jeter
CN101817879A (zh) 2009-02-26 2010-09-01 中国科学院遗传与发育生物学研究所 金属硫蛋白及其编码基因与应用
NZ596603A (en) 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
AU2010291902A1 (en) * 2009-09-14 2012-04-05 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
KR20120113651A (ko) 2009-12-22 2012-10-15 파나소닉 주식회사 광 디스크 장치, 광 디스크 제어 방법 및 집적 회로
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
EP2640742B1 (fr) 2010-11-19 2018-08-15 MorphoSys AG Collection de sequences d'anticorps et leur utilisations
WO2013158859A1 (fr) 2012-04-18 2013-10-24 Cell Signaling Technology, Inc. Egfr et ros1 dans les cancers
SG11202001549UA (en) 2017-08-21 2020-03-30 Adagene Inc Dynamic human antibody light chain libraries
AU2017428737B2 (en) * 2017-08-21 2024-02-15 Adagene Inc. Dynamic human heavy chain antibody libraries
WO2022067020A1 (fr) * 2020-09-24 2022-03-31 The Broad Institute, Inc. Plateforme d'ingénierie d'anticorps acellulaires et anticorps neutralisants contre le sars-cov-2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988006630A1 (fr) * 1987-03-02 1988-09-07 Genex Corporation Procede de preparation de molecules de liaison

Also Published As

Publication number Publication date
IE910336A1 (en) 1991-08-14
EP0440146A2 (fr) 1991-08-07
AU7011591A (en) 1991-08-08
DE4002897A1 (de) 1991-08-08
ATE145427T1 (de) 1996-12-15
GR3022131T3 (en) 1997-03-31
CA2035384A1 (fr) 1991-08-02
DE4003880A1 (de) 1991-08-14
EP0440146B1 (fr) 1996-11-20
ES2097157T3 (es) 1997-04-01
PT96624A (pt) 1991-11-29
IE75220B1 (en) 1997-08-27
US5840479A (en) 1998-11-24
PT96624B (pt) 1998-07-31
DE59108350D1 (de) 1997-01-02
KR100221897B1 (ko) 1999-10-01
KR910021474A (ko) 1991-12-20
JPH04211395A (ja) 1992-08-03
AU638535B2 (en) 1993-07-01
CA2035384C (fr) 2003-07-08
EP0440146A3 (en) 1992-07-15

Similar Documents

Publication Publication Date Title
AU638535B2 (en) Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")
AU628948B2 (en) Monoclonal antibodies (mabs) against tumor-associated antigens, the preparation and use thereof
NO985468L (no) Antistoff og diagnostisk preparat omfattende dette
GEP20063752B (en) Humanized Anti-LT-Beta-R Antibodies
RU2012102323A (ru) Способ лечения ревматоидного артрита посредством лекарственного препарата на основе выделенного человеческого антитела или его антигенсвязывающего фрагмента
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
MY111682A (en) Altered antibodies and their preparations.
IL135221A0 (en) Natural humanized antibody and methods for the preparation thereof
CU23292B7 (es) Anticuerpos monoclonales humanos de ctla-4
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
DK0787135T3 (da) Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh
CY1107785T1 (el) Χρηση του βασιλιξιμαμπ στη θεραπεια της ρευματοειδους αρθριτιδας ´η νοσων του δερματος
ATE134649T1 (de) Arzneimittel und verfahren zur behandlung von erworbenem immundefizienzsyndrom (aids) und aids- verwandtem komplex unter verwendung von karbohydratspezifischen antikörpern
DE68912165D1 (de) Monoklonaler Antikörper, der fähig ist, ein mit humaner Arteriosklerose assoziiertes Antigen zu erkennen und Verfahren zu seiner Herstellung.
KR930013103A (ko) 종양 관련의 모노클로날 항체 88bv59
Shroba The development and characterization of a murine monoclonal antibody directed against human HLA class II-DR antigenic determinants.